Blood-marker guided add-on treatment for major depression
Treatments studied
Part of Mental health clinical trials.
This study tests whether doctors can choose the best add-on immune-related treatment for people with major depressive disorder by using inflammation blood tests. It’s meant for people whose depression has not improved enough with their current antidepressant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re 18 to 65 years old and can give consent and take pills by mouth
- You’ve been diagnosed with major depressive disorder by a structured interview, and this episode hasn’t improved on your current antidepressant
- Your antidepressant dose has been stable for at least 4 weeks (6 weeks for fluoxetine), and you don’t plan to change it during the study
- You don’t have certain other mental health conditions like bipolar disorder, psychosis, or substance/alcohol use disorder
- You’re not using medicines that strongly affect the immune system (such as immunosuppressants or immunostimulants) within the last 21 days
- If you can become pregnant, you agree to reliable birth control and a pregnancy test; you can’t be pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether anti-inflammatory drugs can help reduce symptoms of depression. If you are currently having a major depressive episode and have tried other treatments, this study may offer a new option.
This trial tests whether a medication that targets inflammation in the body can help relieve depression symptoms. You will have blood tests and an MRI to see how your brain and immune system respond.
This trial tests whether adding the antibiotic minocycline to your current antidepressant helps people with both depression and obesity. It aims to see if reducing inflammation can improve mood.
This trial tests a medication called tocilizumab, which targets inflammation, to see if it can improve symptoms of major depression in people with signs of inflammation. You may be eligible if you have depression with a high monocyte count and significant loss of interest or pleasure.
This trial tests if a medicine called infliximab, given through an IV, can help improve thinking and memory problems in people with moderate to severe depression who also have high inflammation levels. It aims to see if lowering inflammation can ease both mood and cognitive symptoms.
This early-stage study tests how your brain responds to an “inflammatory challenge” in people with major depressive disorder and in healthy volunteers. It may help researchers understand the immune-to-brain link in depression and guide future treatments.
Hear when a new Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.